An analysis of pharmacokinetics data on FVIII products for hemophilia A has shown that extended half‐life (EHL) FVIII products have greater area under the curve, indicating greater FVIII levels over time compared to standard half‐life products [10]. This evidence concerns the gene F8 and hemophilia A.